Helix's 15min chart triggers MACD Death Cross, KDJ Death Cross.

According to Helix's 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered on August 11, 2025 at 13:00. This indicates that the stock price has the potential to continue declining, as the momentum of the stock price is shifting towards the downside and may further decrease.

Helix Acquisition Corp. II (HLXB), a special purpose acquisition company (SPAC) sponsored by affiliates of Cormorant Asset Management, has retained approximately $120 million in its trust account after redemptions by public shareholders. This amount represents more than 60% of the cash held in trust, according to a press release dated August 6, 2025 [1].

The redemption rate of 60% is one of the second lowest for a biotech de-SPAC transaction since 2022. The gross proceeds from the trust account and private placement (PIPE) financing are expected to total approximately $382 million, with $120 million from the trust account and approximately $261 million from the PIPE financing led by Cormorant Asset Management and including several other investors [1].

The transaction is expected to raise a significant amount of capital, which will be used to fund the business combination with BridgeBio Oncology Therapeutics (BBOT). BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. The combined company aims to improve outcomes for patients with cancers driven by these prevalent oncogenes.

The business combination is subject to the satisfaction or waiver of closing conditions. Both Helix and BBOT intend to proceed expeditiously with the closing of the transaction.

In addition to the financial implications, the technical analysis of Helix's stock also provides insights. According to the 15-minute chart, a MACD Death Cross and KDJ Death Cross were triggered on August 11, 2025, at 13:00. This indicates a potential shift in the stock price's momentum towards the downside, suggesting that the stock price may continue to decline [2].

References:
[1] https://www.globenewswire.com/news-release/2025/08/06/3128242/0/en/Helix-Acquisition-Corp-II-Retains-More-than-60-of-Trust-Account-after-Redemptions-in-connection-with-Business-Combination-with-BridgeBio-Oncology-Therapeutics.html
[2] (Provided source material for the technical analysis)